Silo Pharma Inc. has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/954,858, titled "Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders." This patent, licensed from Columbia University, will strengthen the intellectual property protection for Silo's lead asset, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The patent is expected to be issued as U.S. Patent No. 12,329,726 on June 17, 2025. According to Eric Weisblum, CEO of Silo, this development enhances protection for the key technology behind their novel PTSD prophylactic, which is being prepared for Phase 1 clinical trials.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466944-en) on June 11, 2025, and is solely responsible for the information contained therein.